IONS

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Roche scraps two Ionis-partnered studies (IONS:NASDAQ)

IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

Canaccord cuts Ionis stock price target on trial miss to $95

Barclays cuts Ionis Pharmaceuticals stock price target on trial miss

Ionis and AstraZeneca: Shares Tank as Phase 3 ATTR-CM Trial Falls Short of Expectations

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals EVP C. Frank Bennett sells $1.7m in stock

Ionis director Allene Diaz sells $863,637 of common stock

Ionis Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $97.43, Implies 15% Upside

Eplontersen’s Failure In ATTR-CM And Its Implications (IONS, AZN, ALNY, BBIO) (NASDAQ:IONS)

AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail - Why You Shouldn't Panic (AZN)

Ionis Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $102.62, Implies 22% Upside

BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’

Jefferies cuts Ionis Pharmaceuticals stock price target on trial miss